These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34325934)

  • 41. Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales.
    Lang JC; Kura K; Garba SM; Elbasha EH; Chen YH
    Vaccine; 2024 Mar; 42(8):1918-1927. PubMed ID: 38368224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
    Rainisch G; Adhikari B; Meltzer MI; Langley G
    Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
    O'Shea TM; Sevick MA; Givner LB
    Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
    Welliver RC
    Semin Perinatol; 1998 Feb; 22(1):87-95. PubMed ID: 9523402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections.
    Weil-Olivier C; Salisbury D; Navarro-Alonso JA; Tzialla C; Zhang Y; Esposito S; Midulla F; Tenenbaum T
    Hum Vaccin Immunother; 2023 Dec; 19(1):2209000. PubMed ID: 37193673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
    Groothuis JR
    Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Respiratory syncytial virus immune globulin: decisions and costs.
    Barton LL; Grant KL; Lemen RJ
    Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunoglobulin for preventing respiratory syncytial virus infection.
    Wang EE; Tang NK
    Cochrane Database Syst Rev; 2000; (2):CD001725. PubMed ID: 10796658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.
    Nyiro JU; Kombe IK; Sande CJ; Kipkoech J; Kiyuka PK; Onyango CO; Munywoki PK; Kinyanjui TM; Nokes DJ
    PLoS One; 2017; 12(5):e0177803. PubMed ID: 28531224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC; Long SS;
    Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
    Lázaro y de Mercado P; Figueras Aloy J; Doménech Martínez E; Echániz Urcelay I; Closa Monasterolo R; Wood Wood MA; Fitch Warner K
    An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials.
    Lee MS; Walker RE; Mendelman PM
    Hum Vaccin; 2005; 1(1):6-11. PubMed ID: 17038832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalence.
    Ortiz JR; Laufer RS; Brunwasser SM; Coulibaly F; Diallo F; Doumbia M; Driscoll AJ; Fell DB; Haidara FC; Hartert TV; Keita AM; Neuzil KM; Snyder BM; Sow S; Fitzpatrick MC
    J Allergy Clin Immunol Glob; 2023 May; 2(2):100092. PubMed ID: 37215432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimating the Economic Impact of Respiratory Syncytial Virus and Other Acute Respiratory Infections Among Infants Receiving Care at a Referral Hospital in Malawi.
    Baral R; Mambule I; Vodicka E; French N; Everett D; Pecenka C; Bar-Zeev N
    J Pediatric Infect Dis Soc; 2020 Dec; 9(6):738-745. PubMed ID: 33347578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B; Müller W
    Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in RSV vaccine research and development - A global agenda.
    Higgins D; Trujillo C; Keech C
    Vaccine; 2016 Jun; 34(26):2870-2875. PubMed ID: 27105562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.
    Vekemans J; Moorthy V; Giersing B; Friede M; Hombach J; Arora N; Modjarrad K; Smith PG; Karron R; Graham B; Kaslow DC
    Vaccine; 2019 Nov; 37(50):7394-7395. PubMed ID: 29395536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.